Abstract Session 7

Co-Chair(s)

• 

  Tanya Wildes, MD, MSCI (she/her/hers)

  Associate Professor of Medicine
  University of Nebraska Medical Center/Nebraska Medicine
  Omaha, Nebraska, United States
• 

  Enrique Ocio, MD, PhD

  Head of the Hematology Department
  Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain
  Santander, Cantabria, Spain

Presentations:

• 5:30 PM – 5:42 PM East Coast USA Time

  OA – 65: Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update
  

  Speaker: María-Victoria Mateos, MD, PhD – University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
• 5:42 PM – 5:54 PM East Coast USA Time

  OA – 04: A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)
  

  Speaker: Bhagirathbhai Dholaria, MBBS (he/him/his) – Vanderbilt-Ingram Cancer Center, Nashville, TN
• 5:54 PM – 6:06 PM East Coast USA Time

  OA – 07: A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma
  

  Speaker: Doris K. Hansen, MD – Moffiitt Cancer Center
• 6:06 PM – 6:18 PM East Coast USA Time

  OA – 12: Interim phase 2 study results of durcabtagene autoleucel (PHE885), a T-Charge™ manufactured BCMA-directed CAR-T cell therapy in patients (pts) with r/r multiple myeloma (RRMM)
  

  Speaker: Andrew Spencer, MBBS FRACP, FRCPA, DM – Alfred Health-Monash University
• 6:18 PM – 6:30 PM East Coast USA Time

  OA – 30: Phase 1 Study Of Anitocabtagene Autoleucel For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients
  

  Speaker: Binod Dhakal, MD, MS – Medical College of Wisconsin, Milwaukee, WI, USA